Journal:

Article Title: Burkholderia pseudomallei Class A ?-Lactamase Mutations That Confer Selective Resistance against Ceftazidime or Clavulanic Acid Inhibition

doi: 10.1128/AAC.47.7.2082-2087.2003

Figure Lengend Snippet: Bacterial strains and plasmids used in this study

Article Snippet: When used, antibiotics were added at the indicated concentrations. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Strain or plasmid Description Reference or source Strains E. coli TOP10 F − mcrA Δ( mrr-hsdRMS-mcrBC ) φ80 lacZ ΔM15 Δ lacX 74 deoR recA1 araD139 Δ( ara-leu ) 7697 galU galK rpsL (Str r ) endA1 nupG Invitrogen E. coli BL21 (DE3) F − ompT hsdS B (r B − m B − ) gal dcm (DE3) pLysS (Cam r ) Invitrogen E. coli BL21 (DE3)pLysS BL21(DE3)pLysS: F − ompT hsdS B (r B − m B − ) gal dcm (DE3) pLysS (Cam r ) Invitrogen B. cepacia K56-2 CF isolate, Toronto, Canada 8 B. mallet ATCC 23344 Type strain (human isolate) USAMRIID a B. pseudomallei 316a Clinical isolate, wild-type phenotype 8 B. pseudomallei 316c Clinical isolate, selectively resistant to ceftazidime 8 B. pseudomallei 365c Clinical isolate, wild-type phenotype 8 B. pseudomallei 365a Clinical isolate, derepressed phenotype 8 B. pseudomallei 392a Clinical isolate, wild-type phenotype 8 B. pseudomallei 392f Clinical isolate, decreased susceptibility to clavulanic acid inhibition 8 B. thailandensis ATCC 700388 Type strain (soil isolate) 16 Plasmids pCR2.1-TOPO Topoisomerase-mediated cloning vector: Ap r Km r Invitrogen pEM7/Zeo Expression vector, Zeo r Invitrogen pUCP31T Broad-host-range vector.

Techniques: Plasmid Preparation, Inhibition, Cloning, Expressing, Clone Assay

Journal: Cell

Article Title: Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope

doi: 10.1016/j.cell.2022.07.002

Figure Lengend Snippet:

Article Snippet: Synthetic genes for HLA A ∗ 02 : 01 , Beta-2-microglobulin ( B2M) , YLQ36 α chain and YLQ36 β chain were designed and codon optimized for Escherichia coli expression, purchased from GeneArt and cloned into the pGEM-T expression vector (Promega).

Techniques: Purification, Recombinant, RNA Extraction, Mutagenesis, Plasmid Preparation, Enzyme-linked Immunosorbent Assay, Staining, Activation Assay, Expressing, Software, Blocking Assay